Literature DB >> 17308732

Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Côte d'Ivoire.

Albert Minga1, Christine Danel, Yao Abo, Lambert Dohoun, Dominique Bonard, Ali Coulibaly, Julien Duvignac, François Dabis, Roger Salamon, Xavier Anglaret.   

Abstract

OBJECTIVE: To estimate the probability of reaching the criteria for starting highly active antiretroviral therapy (HAART) in a prospective cohort of adult HIV-1 seroconverters in Abidjan, Côte d'Ivoire.
METHODS: We recruited participants from HIV-positive donors at the blood bank of Abidjan for whom the delay since the estimated date of seroconversion (midpoint between last negative and first positive HIV-1 test) was < 36 months. Participants were offered early trimethoprim-sulfamethoxazole (cotrimoxazole) prophylaxis, twice-yearly measurement of CD4 count and we made standardized records of morbidity. We used the Kaplan-Meier method to estimate the probability of reaching the criteria for starting HAART according to WHO 2006 guidelines.
FINDINGS: 217 adults (77 women (35%)) were followed up during 668 person-years (PY). The most frequent diseases recorded were mild bacterial diseases (6.0 per 100 PY), malaria (3.6/100 PY), herpes zoster (3.4/100 PY), severe bacterial diseases (3.1/100 PY) and tuberculosis (2.1/100 PY). The probability of reaching the WHO 2006 criteria for HAART initiation was estimated at 0.09, 0.16, 0.24, 0.36 and 0.44 at 1, 2, 3, 4 and 5 years, respectively.
CONCLUSION: Our data underline the incidence of the early HIV morbidity in an Ivorian adult population and provide support for HIV testing to be made more readily available and for early follow-up of HIV-infected adults in West Africa.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17308732      PMCID: PMC2636271          DOI: 10.2471/blt.06.032292

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  16 in total

1.  HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?

Authors:  Dilys Morgan; Cedric Mahe; Billy Mayanja; J Martin Okongo; Rosemary Lubega; James A G Whitworth
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

2.  Should cotrimoxazole prophylaxis be taken by all adults with HIV in Africa?

Authors:  Jonathan Mermin; John R Lule; John P Ekwaru; Christian Pitter
Journal:  AIDS       Date:  2005-05-20       Impact factor: 4.177

3.  Missing data in longitudinal studies.

Authors:  N M Laird
Journal:  Stat Med       Date:  1988 Jan-Feb       Impact factor: 2.373

4.  Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Côte d'Ivoire.

Authors:  Xavier Anglaret; Eugène Messou; Timothée Ouassa; Siaka Toure; Nicole Dakoury-Dogbo; Patrice Combe; Allassane Mahassadi; Catherine Seyler; Thérèse N'Dri-Yoman; Roger Salamon
Journal:  AIDS       Date:  2003-03-07       Impact factor: 4.177

5.  Clinical and biological evolution of HIV-1 seroconverters in Abidjan, Côte d'Ivoire, 1997-2000.

Authors:  Roger Salamon; Catherine Marimoutou; Daniel Ekra; Albert Minga; Eric Nerrienet; Catherine Huët; Gwenola Gourvellec; Dominique Bonard; Issouf Coulibaly; Patrice Combe; François Dabis; Alain Bondurand; Luc Montagnier
Journal:  J Acquir Immune Defic Syndr       Date:  2002-02-01       Impact factor: 3.731

6.  Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection.

Authors:  O A Anzala; N J Nagelkerke; J J Bwayo; D Holton; S Moses; E N Ngugi; J O Ndinya-Achola; F A Plummer
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

7.  Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.

Authors:  Gaston Djomand; Thierry Roels; Tedd Ellerbrock; Debra Hanson; Fabien Diomande; Bondo Monga; Chantal Maurice; John Nkengasong; Regina Konan-Koko; Auguste Kadio; Stefan Wiktor; Eve Lackritz; Joseph Saba; Terence Chorba
Journal:  AIDS       Date:  2003-07       Impact factor: 4.177

8.  The natural history of HIV-1 infection in young Thai men after seroconversion.

Authors:  Ram Rangsin; Joseph Chiu; Chirasak Khamboonruang; Narongrid Sirisopana; Sakol Eiumtrakul; Arthur E Brown; Merlin Robb; Chris Beyrer; Cholticha Ruangyuttikarn; Lauri E Markowitz; Kenrad E Nelson
Journal:  J Acquir Immune Defic Syndr       Date:  2004-05-01       Impact factor: 3.731

9.  The mortality and pathology of HIV infection in a west African city.

Authors:  S B Lucas; A Hounnou; C Peacock; A Beaumel; G Djomand; J M N'Gbichi; K Yeboue; M Hondé; M Diomande; C Giordano
Journal:  AIDS       Date:  1993-12       Impact factor: 4.177

10.  Broad spectrum of coreceptor usage and rapid disease progression in HIV-1-infected individuals from Central African Republic.

Authors:  Evelyne Bégaud; Gilbert Feindirongai; Pierre Versmisse; Julienne Ipero; Josiane Léal; Yves Germani; Jacques Morvan; Hervé Fleury; Michaela Müller-Trutwin; Françoise Barré-Sinoussi; Gianfranco Pancino
Journal:  AIDS Res Hum Retroviruses       Date:  2003-07       Impact factor: 2.205

View more
  20 in total

1.  CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters.

Authors:  Albert K Minga; Charlotte Lewden; Delphine Gabillard; Germain I Bomisso; Thomas-d'aquin Toni; Arlette A Emième; Vincent Yapo; André Inwoley; Roger Salamon; Xavier Anglaret
Journal:  AIDS       Date:  2011-03-27       Impact factor: 4.177

2.  Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis.

Authors:  Xavier Anglaret; Callie A Scott; Rochelle P Walensky; Eric Ouattara; Elena Losina; Raoul Moh; Jessica E Becker; Lauren Uhler; Christine Danel; Eugene Messou; Serge Eholié; Kenneth A Freedberg
Journal:  Antivir Ther       Date:  2012-07-18

3.  Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.

Authors:  Eric N Ouattara; Xavier Anglaret; Angela Y Wong; Jennifer Chu; Heather E Hsu; Christine Danel; Serge Eholié; Raoul Moh; Delphine Gabillard; Rochelle P Walensky; Kenneth A Freedberg
Journal:  AIDS       Date:  2012-03-13       Impact factor: 4.177

4.  Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.

Authors:  Eugène Messou; Marie-Laure Chaix; Delphine Gabillard; Albert Minga; Elena Losina; Vincent Yapo; Martial Kouakou; Christine Danel; Caroline Sloan; Christine Rouzioux; Kenneth A Freedberg; Xavier Anglaret
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

5.  Short communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Côte d'Ivoire.

Authors:  Albert Minga; Charlotte Lewden; Lambert Dohoun; Yao Abo; Arlette Emieme; Ali Coulibaly; Roger Salamon; Serge Eholié; Xavier Anglaret; Christine Danel
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09       Impact factor: 2.205

6.  Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness.

Authors:  April D Kimmel; Milton C Weinstein; Xavier Anglaret; Sue J Goldie; Elena Losina; Yazdan Yazdanpanah; Eugène Messou; Kara L Cotich; Rochelle P Walensky; Kenneth A Freedberg
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

7.  CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa.

Authors:  Charlotte Lewden; Delphine Gabillard; Albert Minga; Didier K Ekouévi; Divine Avit; Issouf Konate; Clarisse Amani-Bossé; Eugène Messou; Patrick Coffie; Abdoulaye Ouedraogo; Christian Laurent; Xavier Anglaret
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

8.  CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.

Authors:  Yazdan Yazdanpanah; Lindsey L Wolf; Xavier Anglaret; Delphine Gabillard; Rochelle P Walensky; Raoul Moh; Christine Danel; Caroline E Sloan; Elena Losina; Kenneth A Freedberg
Journal:  Antivir Ther       Date:  2010

9.  Low HIV testing rates among tuberculosis patients in Kampala, Uganda.

Authors:  Ibrahim Sendagire; Imke Schreuder; Mesach Mubiru; Maarten Schim van der Loeff; Frank Cobelens; Joseph Konde-Lule
Journal:  BMC Public Health       Date:  2010-03-31       Impact factor: 3.295

10.  Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.

Authors:  Elena Losina; Hapsatou Touré; Lauren M Uhler; Xavier Anglaret; A David Paltiel; Eric Balestre; Rochelle P Walensky; Eugène Messou; Milton C Weinstein; François Dabis; Kenneth A Freedberg
Journal:  PLoS Med       Date:  2009-10-27       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.